Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cellulitis due to Haemophilus influenzae type B in adults has only recently been reported. We report a case in which the patient's antibody levels documented an immunologic response to the organism. The efficacy of a new cephalosporin antibiotic, cefoxitin sodium, in treating this infection also was established. Cefoxitin has activity against ampicillin-resistant H influenzae and would be an alternative in treating H influenzae cellulitis.
 ...
PMID:Haemophilus influenzae cellulitis in an adult. 31 24

Cefoxitin, a parenteral cephamycin beta-lactam antibiotic, was evaluated for safety and efficacy in children with bacterial infections other than meningitis. Twentysix patients between 3 months and 7 years of age were treated with 80 to 160 mg/kg per day. The most common diagnoses were cellulitis (13 patients), pneumonia (5 patients), and bone and joint infection (4 patients). Nine patients were bacteremic. The most frequently recovered pathogens were Staphylococcus aureus (six patients), Haemophilus influenzae (four patients), and Streptococcus pneumoniae (three patients). All organisms were susceptible to cefoxitin. All 26 children were considered improved or cured. No severe adverse reactions were encountered. Phlebitis (4%), eosinophilia (12%), and elevated liver function tests (4%) were associated with therapy. Cefoxitin appears to be a safe, effective, and well-tolerated antibiotic when used in children with susceptible bacterial infections other than meningitis.
 ...
PMID:Clinical and bacteriological evaluation of cefoxitin therapy in children. 48 29

A total of 30 recently isolated strains of Haemophilus influenzae were tested for in vitro susceptibility to seven cephalosporins. In order of bacteriostatic effectiveness, the in vitro activity of the antibiotics studied was: cephapirin (median MIC = 0.78 mcg/ml), cephalothin (median MIC = 1.56 mcg/ml), cefazolin (median MIC: 1.56 mcg/ml), cephaloridine (median MIC = 3.12 mcg/ml), cefoxitin (median MIC = 3.12 mcg/ml), cephradine (median MIC = 12.5 mcg/ml) and cephalexin (median MIC = 25 mcg/ml). The bactericidal effectiveness of the seven compounds was studied against one of these strains. No drug was able to kill the selected strain in less than 6 hrs, even at 100 mcg per ml. Cefoxitin exhibited the best bactericidal effects, closely followed by cefazolin and cephapirin.
 ...
PMID:In vitro bacteriostatic and bactericidal activities of 7 cephalosporin antibiotics on Haemophilus influenzae. 108 73

The cephalosporins may currently be classified according to their relative susceptibility to beta-lactamases. Cefoxitin, cefamandole, cefatrizine, and cephanone are relatively resistant to the gram-negative beta-lactamases, whereas cephalothin, cefamandole, and cefoxitin are resistant to staphylococcal beta-lactamase. Although the inhibitory activity of cephalothin is representative of that of cephaloridine, cephalexin, cefazolin, cephapirin, cephacetrile, and cephradine, there are significant differences between its activity and that of cefoxitin, cefamandole, and cefatrizine, especially against Enterobacter, Serratia, indole-positive Proteeae, Bacteroides fragilis, and ampicillin-resistant Haemophilus influenzae.
 ...
PMID:The in vitro spectrum of the cephalosporins. 126 95

The US guidelines for prevention and management of the difficult to diagnose symptomatic pelvic inflammatory disease (PID), which affects approximately 1 million every year, include microbial etiology and pathogenesis, the magnitude of the problem in terms of epidemiology and financial impact, risk assessment, prevention, diagnosis, treatment, and surveillance. The etiology of PID reveals multiple organisms, though mostly C. trachomatis and N. gonorrhoea. PID includes acute, silent, and atypical. C. trachomatis has been isolated in 20-40% of PID cases, while N. gonorrhoea in 27-80% of cervical cases. Other anaerobic bacteria isolated, which comprise 25-50% of acute cases, are Gardnerella vaginalis, Streptococcus species, Escherichia coli, and Hemophilus influenzae. PID results when organisms from the endocervix spread to the endometrium and fallopian tube mucosa. Contributing factors are IUD user's hormonal changes during menses (within 7 days of onset of menses), retrograde menses, and virulent characteristics of acute chlamydial and gonococcal PID. The estimated cost of PID for 1990 was $4.2 billion for 25 million in outpatient care and 275,000 hospitalized. Sexual practice related to the risk of PID are having sex with someone with STD, a young age at first intercourse, multiple sex partners, a high frequency of sexual intercourse and new partners within 30 days. Barrier methods (mechanical or chemical) decrease risk. Inconsistent risk is associated with oral contraceptive use and douching, but IUD's have an increased risk of adverse consequences and further transmission. Recommended action is community health promotion of education, as well as prompt and available clinical service, partner notification, training of health care providers, and routine screening. Individuals must self protect. Clinical diagnosis is difficult and imprecise. Minimum criteria for clinical diagnosis are lower abdominal pain, bilateral adnexal tenderness, cervical motion tenderness. Severe cases require oral temperature 38.3 Centigrade, abnormal cervical or vaginal discharge, elevated erythrocyte sedimentation rate and/or C-reactive protein, culture for N. gonorrhoea and non-cervical tests for C. trachomatis, and optionally endometrial biopsy, tubo-ovarian sonography, and laparoscopy. Failure to meet these criteria should not be withholding therapy. Sensitivity to the emotional needs and careful follow-up are necessary. Inpatient treatment recommendations are broad spectrum regimens such as: Cefoxitin plus doxycycline; for outpatients, cefoxitin plus doxycycline or tetracycline (erthyromycin may be substituted).
 ...
PMID:Pelvic inflammatory disease: guidelines for prevention and management. 203 5

Cefamandole and cefoxitin, introduced only 7 years ago, are now the most commonly prescribed parenteral antibiotics in the United States. These drugs are similar to the first-generation cephalosporins in toxicity, but their in-vitro spectrum of activity is greater. Their serum half-lives are longer than those of cephalothin and cephapirin but shorter than that of cefazolin. Although cefamandole has been recommended in empiric therapy for patients with community-acquired pneumonia and as a prophylactic agent for patients having various surgical procedures, other regimens are less expensive and just as effective. Cefamandole should not be used to treat intra-abdominal, enterobacter, or ampicillin-resistant Haemophilus influenzae infections. Cefoxitin is effective in the treatment and prevention of mixed aerobic-anaerobic skin and soft-tissue, intra-abdominal, gynecologic, and penicillinase-producing, spectinomycin-resistant Neisseria gonorrhoeae infections. Cefoxitin represents a greater advance than cefamandole in our continuing search for safe and more effective antimicrobial agents.
 ...
PMID:Cefamandole and cefoxitin. 389 Jun 58

Sixty-three strains of Haemophilus species, 38 of which were beta-lactamase producers (37 H. influenzae type b, 1 H. parainfluenzae) and 25 of which were beta-lactamase negative (20 H. influenzae, 5 H. parainfluenzae), were tested for susceptibility to cefoxitin, moxalactam (LY127935) (Lilly), cefsulodin (CGP 7174 E, Ciba), and cefoperazone (T 1551, Pfizer). Cefsulodin was relatively inactive at both low and high inocula. LY127935 and cefoperazone displayed inoculum-dependent bactericidal activity. Cefoxitin displayed little inoculum effect against beta-lactamase-producing strains: 8 and 16 microgram/ml killed at least 90% of those tested at 10(4) and 10(6) colony-forming units per ml, respectively.
 ...
PMID:Effect of inoculum size and beta-lactamase production on in vitro activity of new cephalosporins against Haemophilus species. 644 75

The in vitro activity of the novel beta-lactam antibiotic, N-formimidoyl thienamycin (N-f thienamycin) has been compared with those of cefoxitin and tobramycin. An agar dilution method was employed. N-f thienamycin was active against all Enterobacteriaceae isolates (MIC less than or equal to 4 mg/l). All Pseudomonas aeruginosa isolates were inhibited by 2 mg/l. N-f thienamycin was also active against Acinetobacter calcoaceticus (96 per cent inhibited by 0.5 mg/l) and Gram-positive cocci. All enterococci were inhibited by 2 mg/l. The drug was active against Haemophilus influenzae (MIC less than or equal to 1 mg/l) and the Bacteroides fragilis group (MIC less than or equal to 0.5 mg/l). Cefoxitin was inactive against most Enterobacter and A. calcoaceticus isolates and all P. aeruginosa and enterococcal isolates. Tobramycin was virtually inactive against Gram-positive cocci other than Staphylococcus aureus. N-f thienamycin thus has a broad spectrum of in vitro activity, greater than that of cefoxitin and tobramycin, and may therefore be useful in the treatment of serious infection, particularly when the aetiology is unknown.
 ...
PMID:N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates. 660 93

Cefoxitin, a parenteral cephamycin beta-lactam antibiotic was prospectively evaluated as a single drug alternative in 31 children with cellulitis and the results of therapy were compared retrospectively with those from prevailing multiple antibiotic therapy for cellulitis in 56 children. Periorbital and lower extremity cellulitis accounted for more than 60% of the cases in both study groups. The most common bacterial agents included Haemophilus influenzae, Staphylococcus aureus, and group A beta-hemolytic Streptococcus. In as many as 50% of the cases, no etiologic agent could be found. In addition to blood cultures, cellulitis leading edge aspirate cultures were helpful in establishing the etiologic diagnosis. Of 52 patients sampled in the combined studies, 21% had positive aspirate cultures in the presence of negative blood cultures. The outcome and mean duration of hospital stay were similar in both groups. No severe adverse reactions were encountered. The mean number of antibiotics used in the retrospective study was three (range 1 to 7) whereas cefoxitin alone was used in the prospective study. All organisms isolated in the prospective study were susceptible to cefoxitin. Single antibiotic therapy with cefoxitin appears to be as safe and as effective in the treatment of cellulitis in children as multiple antibiotic therapy.
 ...
PMID:Cellulitis: treatment with cefoxitin compared with multiple antibiotic therapy. 701 65

Cefoxitin (CFX) was evaluated for its safety and efficacy in children. Fifteen patients were treated with 73-125 mg/kg per day of CFX by intravenous administrations. The diagnosis of the patients were acute pharyngitis (4), pneumonia (2), pertussis and pneumonia (1), urinary tract infection (3); and the remaining 5 patients were esteemed to have nonbacterial infections. All the 10 patients of bacterial infections were cured after the CFX therapy. The pathogens recovered were Streptococcus pyogenes (1), Streptococcus pneumoniae (3), Haemophilus influenzae (2), Escherichia coli (2), enteropathogenic Escherichia coli (1), and Klebsiella pneumoniae (1). All the strains isolated were susceptible to CFX, but the 2 isolates of Haemophilus influenzae had relatively high MIC values (12.5 mcg/ml). Diarrhea (3 cases) and transient neutropenia (1 case) were found to be associated with the CFX therapy. However, no severe adverse reactions were encountered. Half-life of the serum level was short (24.1 minutes) and excretion into the urine was rapid. CSF concentration obtained 30 minutes after an intravenous injection of 50 mg/kg of CFX in 1 case with inflamed meninges was considerably high (8.3 mcg/ml). CFX appears to be a safe and effective antibiotic when used in children with susceptible bacterial infections.
 ...
PMID:[Clinical evaluation of cefoxitin in children (author's transl)]. 728 18


1